Combination Chemotherapy and Bone Marrow Transplant in Treating Patients With Refractory or Recurrent Ovarian Cancer

You may be eligible if

• DISEASE CHARACTERISTICS:
• Diagnosis of refractory or relapsed ovarian epithelial cancer
• * Must have failed prior regimen containing cisplatin or carboplatin
• Bidimensionally measurable or evaluable disease
• * Serial CA-125 antigen titers or cytologically positive pleural effusion and/or ascites acceptable as evaluable disease
• Autologous bone marrow harvest of greater than 1.2 x 10 to the eighth nucleated cells/kg required before study entry
• No evidence of tumor at marrow harvest sites by bilateral bone marrow aspirates and biopsies, pelvic x-ray, and bone scan
• CNS involvement allowed
• PATIENT CHARACTERISTICS:
• Age:
• Under 65
• Performance status:
• SWOG 0-2
• Life expectancy:
• At least 8 weeks
• Hematopoietic:
• WBC greater than 3,500/mm\^3
• Platelet count greater than 100,000/mm\^3
• Hemoglobin greater than 10.0 g/dL
• Hepatic:
• Bilirubin less than 2.0 mg/dL
• SGOT and SGPT less than 2 times upper limit of normal
• Renal:
• Creatinine clearance greater than 60 mL/min
• No prior hemorrhagic cystitis
• Cardiovascular:
• LVEF greater than 45% by MUGA scan
• Other:
• No hearing loss in voice tones
• No active infection
• No psychological contraindication to study treatment
• Not pregnant
• Negative pregnancy test
• HIV negative
• General medical condition must allow general anesthesia
• PRIOR CONCURRENT THERAPY:
• Biologic therapy:
• See Disease Characteristics
• No prior bone marrow transplantation
• More than 4 weeks since other prior biologic therapy and recovered
• Chemotherapy:
• See Disease Characteristics
• More than 4 weeks since prior chemotherapy (at least 6 weeks for nitrosoureas or mitomycin) and recovered
• Endocrine therapy:
• Not specified
• Radiotherapy:
• More than 4 weeks since prior radiotherapy and recovered
• Surgery:
• Not specified